Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim bridging study in non-Asian adults with severe aplastic anemia
2022-001257-22Phase 2Active
- Sponsor
- Amgen
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of romiplostim in aplastic anemia (2 arms), sponsored by Amgen. Started Aug 2022; status: active.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on 2022-001257-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001257-22.